Was it $24m in sales, or net profit on Qbrexza?
As can be seen below, Euroz Hartleys are suggesting BOT's SB net sales in 2025 of $175m, but due to royalties, milestones, costs and tax - an after tax profit of only $22m. Could that be a similar scenario for Eli Lilly and their purchase of Qbrexza maybe?
Ann: Investor Webinar Presentation, page-57
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $2.548M | 6.766M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 96148 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 782479 | 9 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |